UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~November~~January 1730, ~~2025~~2026

HARROW, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-35814

45-0567010

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1A Burton Hills Blvd., Suite 200
Nashville, Tennessee		37215
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (615) 733-4730

Not Applicable ~~(Former Name or Former Address, if Changed Since Last Report)~~

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name onof exchange on which registered
Common Stock, $0.001 par value per share		HROW		The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934: Emerging growth company ☐

If ~~any~~an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.0102. ~~Completion~~Results of ~~Acquisition~~Operations orand ~~Disposition~~Financial ~~of Assets~~Condition.

On ~~November~~February 172, ~~2025~~2026, Harrow, Inc. (the “Company”) ~~completed~~issued ~~the~~a ~~previously~~press ~~announced~~release, ~~acquisition~~which, ofamong ~~Melt~~other ~~Pharmaceuticals~~things, ~~Inc. (“Melt”)~~reaffirmed ~~pursuant to~~ the ~~Agreement~~Company’s full-year ~~and~~2025 ~~Plan~~revenue guidance of ~~Merger,~~between ~~dated~~$270 ~~September~~million ~~24,~~and ~~2025~~$280 ~~(the~~million. ~~“Merger~~A ~~Agreement”),~~copy ~~by and~~of ~~among~~ the ~~Company,~~press ~~Harrow~~release ~~Acquisition~~is ~~Sub,~~furnished ~~Inc~~as Exhibit 99.,1 ~~Melt,~~to this ~~and~~Current ~~the~~Report ~~stockholder~~on ~~representative~~Form 8-K.

The ~~material~~information ~~terms~~in this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the ~~Merger~~Securities ~~Agreement~~Exchange Act ~~and~~of 1934, as amended (the ~~related~~“Exchange ~~milestone~~Act”), ~~payment~~nor ~~agreement~~shall ~~were~~it ~~previously~~be ~~described~~deemed incorporated by reference in ~~the~~any ~~Company’s~~filing ~~Current~~under the Securities ~~Report~~Act onof ~~Form~~1933, ~~8-K~~as ~~filed~~amended, onor ~~September~~the ~~26,~~Exchange ~~2025~~Act, ~~which~~except ~~description~~as isshall ~~incorporated~~be ~~herein~~expressly set forth by specific reference in such filing.

AtItem ~~closing, the Company paid approximately $4~~5.302. ~~million~~Departure inof ~~cash~~Directors asor ~~initial~~Certain ~~consideration~~Officers; ~~for~~Election ~~the~~of ~~remaining~~Directors; ~~equity~~Appointment ~~interests~~ of ~~Melt.~~Certain ~~The contingent~~Officers; ~~regulatory~~Compensatory ~~and~~Arrangements of ~~commercial~~Certain ~~milestone payments described in the Company’s September 26, 2025 Form 8-K remain unchanged.~~Officers

~~All~~On ~~closing~~January ~~conditions~~30, ~~under~~2026, the ~~Merger~~Company ~~Agreement~~appointed ~~were~~Patrick ~~satisfied~~W. ~~or waived~~Sullivan, ~~and~~age ~~the~~50, ~~merger~~as ~~became~~Chief ~~effective~~Commercial onOfficer ~~November~~of 17the Company, ~~2025~~effective immediately.

~~Item~~Patrick 3W.02 ~~Unregistered~~Sullivan ~~Sales~~joined the Company as Head of ~~Equity~~Commercial ~~Securities~~in August 2025, bringing over 25 years of commercial leadership experience. Before joining the Company, Mr. Sullivan was Vice President of Marketing, Neurology Portfolio at Corium Therapeutics, where he led U.S. commercialization and launches in ADHD and dementia. Previously, he served as Global Commercial Head and Executive Director at AstraZeneca, directing the launch of Evrenzo® (roxadustat), a first-in-class anemia therapy. Earlier in his career, he held leadership roles at Shire, Adolor, Novartis, and Bayer. Mr. Sullivan holds a B.S. in Business Administration from Widener University.

ToThere ~~the~~are ~~extent~~no ~~applicable,~~arrangements ~~the~~or ~~disclosure~~understandings ~~included~~between ~~in Item 2~~Mr.01 ofSullivan ~~this~~and ~~Current~~any ~~Report~~other onperson Form 8-K regarding the potential future issuance of shares of the Company’s common stock in connection with the Melt acquisition is incorporated by reference into this Item 3.02. Any such shares would be issued pursuant to ~~the~~which ~~exemption~~he ~~from~~was ~~registration~~selected ~~provided~~as byofficer ~~Section 4(a)(2)~~ of the ~~Securities Act of 1933, as amended~~Company.

~~Item~~Mr. 8Sullivan does not have any family relationships with any director or executive officer of the Company, and there are no related party transactions involving Mr.01 ~~Other~~Sullivan ~~Events~~that would require disclosure under Item 404(a) of Regulation S-K.

OnIn ~~November~~connection ~~18,~~with ~~2025~~Mr. Sullivan’s appointment, the Company ~~issued~~entered ainto ~~press~~an ~~release~~Offer ~~announcing~~Letter ~~the~~dated ~~closing~~January of30, ~~the~~2026 ~~Melt acquisition. A copy of~~ (the ~~press~~“Offer ~~release~~Letter”), ispursuant ~~filed~~to aswhich ~~Exhibit~~he ~~99.1~~will ~~hereto.~~receive:

~~Item 9.01.~~● ~~Financial~~Base ~~Statements~~Salary of $425,000 per year; ● Target annual bonus opportunity of 40% of base compensation, subject to achievement of targets agreed upon; and ~~Exhibits~~● 40,000 restricted stock units (RSUs): 25,000 RSUs will vest when Harrow’s revenue reaches $230,000,000 in a calendar quarterly period, 15,000 RSUs will vest after 3 years from the date of the award.

(d)		Exhibits
99.1		Press Release issued by Harrow, Inc. on November 18, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

The foregoing description of the Offer Letter is qualified in its entirety by reference to the full text of the Offer Letter, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

No.		Description

10.1		Offer Letter dated January 30, 2026 by and between Harrow, Inc and Patrick W. Sullivan

99.1		Press release, dated February 2, 2026

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HARROW, INC.
Dated: February 2, 2026	HARROW, INC.
Dated: November 18, 2025	By:	/s/ Andrew R. Boll
	By:	/s/ Andrew R. Boll
	Name:	Andrew R. Boll
		Andrew R. Boll
	Title:	President & Chief Financial Officer
		President and Chief Financial Officer

Filing Compare · HARROW, INC.